Total Raised

$255M

Deal Terms

2

PathAI Funding, PathAI Valuation & PathAI Revenue

6 Fundings

PathAI's latest funding round was a Series C for $165M on May 18, 2021.

PathAI's valuation in April 2019 was $375M.

PathAI's latest post-money valuation is from April 2019.

Sign up for a free trial to see PathAI's valuations in November 2017 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/18/2021

Series C

$165M

0

FY undefined

5

11/4/2019

Series B - II

$99M

0

FY undefined

10

7/24/2019

Corporate Minority

0

FY undefined

10

4/17/2019

Series B

$99M

$375M

0

FY undefined

10

11/2/2017

Series A

$99M

$99M

0

FY undefined

10

Date

5/18/2021

11/4/2019

7/24/2019

4/17/2019

11/2/2017

Round

Series C

Series B - II

Corporate Minority

Series B

Series A

Amount

$165M

$99M

$99M

$99M

Investors

Valuation

$375M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

5

10

10

10

10

PathAI Deal Terms

2 Deal Terms

PathAI's deal structure is available for 2 funding rounds, including their Series B from April 17, 2019.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

$99M

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

$99M

$99M

PathAI Acquisitions

1 Acquisition

PathAI acquired 1 company. Their latest acquisition was Poplar Healthcare on July 26, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/26/2021

$99M

Acquired

2

Date

7/26/2021

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

2

You May Also Like

P
Paige

Paige delivers AI-powered digital diagnostics and biomarkers for pathologists, oncologists, and the R&D community worldwide, while also working closely with biopharma companies to create custom diagnostic solutions and drug development technologies to improve patient care. The firm's target customers include pathologists, hospital leads/chairs as well as life sciences research and translational teams.

Proscia Logo
Proscia

Proscia is a software company focused on transforming cancer research and diagnosis. With the company's Concentriq digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries.

Ibex Medical Analytics Logo
Ibex Medical Analytics

Ibex Medical Analytics develops AI-driven clinical decision support tools that help pathologists deliver more efficient, metric-driven, objective and accurate diagnosis. Ibex develops a diagnostic system that uses computer vision, machine learning, and electronic medical records to confirm cancer diagnoses of tissue biopsies. The company was founded in 2016 and is based in Israel.

Owkin Logo
Owkin

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology.

DeepBio Logo
DeepBio

DeepBio is a developer of prostate cancer diagnosis software. The company's product features a convolutional neural network that detects and grades prostate cancer from needle biopsy images.

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.